This educational activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc.
Supportive Care in Chronic Lymphocytic Leukemia
Sandra E. Kurtin, RN, MS, AOCN®, ANP-C
The University of Arizona Cancer Center
CLL patients are at risk for developing complications such as autoimmunity, infections, and tumor lysis syndrome. Advanced practitioners need to understand these complications, including monitoring, preventive measures, and management strategies. This activity will provide the advanced practitioner with key takeaways needed to face the challenges in caring for CLL-related complications and ensure the best patient outcomes.
Management of Newly Diagnosed Chronic Lymphocytic Leukemia Patients
Relapsed or Refractory Chronic Lymphocytic Leukemia and the Management of Chronic Lymphocytic Leukemia Patients Treated With Immunotherapy
Risk-Stratified Treatment in Chronic Lymphocytic Leukemia
What test should an advanced practitioner order if CLL is suspected?
What are the differences in the side effect profile between the monoclonal antibody treatments for CLL?
What are the most important prognostic factors in CLL?
How does Bruton's tyrosine kinase differ from other tyrosine kinases, and what role does it play in CLL and treatment?
The monoclonal antibodies rituximab, obinutuzumab, and ofatumumab all target CD20; how do they differ in their indications in the treatment of CLL?
What should advanced practitioners look for with CLL patients that also have lymphocytosis?
Bone Marrow Biopsy Demonstration Video